Tirzepatide (Zepbound / Mounjaro) Tirzepatide activates both GLP-1 and GIP receptors simultaneously a dual mechanism that produces significantly greater weight loss than GLP-1 alone
This interval allows: GI side effects (nausea, vomiting, diarrhea) from the current dose level to subside The body to adapt to the rate of gastric emptying at that dose Clinicians to assess tolerability before increasing further Time to reach maximum dose week 20 (after five four-week steps: 1mg, 2mg, 4mg, 8mg, 12mg)
This stepwise escalation principle mirrors the approach used for licensed medicines such as semaglutide (Wegovy, UK SmPC available via the electronic Medicines Compendium) and tirzepatide (Mounjaro, UK SmPC available via the electronic Medicines Compendium), both of which are approved by the MHRA and recommended within relevant NICE guidance for specific indications
This delivery method is marketed as being gentler on the stomach while reducing the risk of digestive discomfort that can occur with oral supplements
Threshold results show how many participants reached specific levels, such as 5%, 10%, or 15% weight loss
This investigational status means that the only legitimate pathway for obtaining pharmaceutical-grade retatrutide for clinical use is through participation in authorized clinical trials
